The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis
British Journal of Dermatology · 17.10.2025 · 193 (5) · 996-998
DOI: 10.1093/bjd/ljaf259 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 28.06.2025. Verfasst von Hendy Kristyanto und 6 weiteren Autor:innen. Beteiligte Einrichtung: European Medicines Agency, Domenico Scarlattilaan 6, 1083HS Amsterdam, the Netherlands. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Atopic dermatitis (AD) and prurigo nodularis (PN) are chronic inflammatory skin diseases that are characterized by intense pruritus. Nemolizumab is the first interleukin-31 blocking agent approved in the EU for the treatment of moderate-to-severe AD and PN. This article summarizes the key benefits and risks associated with nemolizumab and provides perspectives on the additional value of nemolizumab in the treatment armamentarium.
Autor:innen und Institutionen
- European Medicines Agency, Domenico Scarlattilaan 6, 1083HS Amsterdam, the Netherlands.
- Swedish Medical Products Agency, Dag Hammarskjolds Vag 42, Uppsala Science Park, 752 37 Uppsala, Sweden.
- Agency for Medicinal Products and Medical Devices of Croatia, Ksaverska Cesta 4, 10000 Zagreb, Croatia.
- Faculdade de Farmácia da Universidade de Lisboa, Avenida Professor Gama Pinto 1649-003 Lisboa, Portugal.
Zitieren
APA
Kristyanto, H., Rey Torre, S., Cunney, A., Dunder, K., Bego, M., Sepodes, B., & Castelnovo, T. (2025). The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. British Journal of Dermatology, 193(5), 996-998. https://doi.org/10.1093/bjd/ljaf259
Vancouver
Kristyanto H, Rey Torre S, Cunney A, Dunder K, Bego M, Sepodes B, et al. The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. British Journal of Dermatology. 2025;193(5):996-998. doi:10.1093/bjd/ljaf259
BibTeX
@article{Kristyanto2025,
author = {Kristyanto, Hendy and Rey Torre, Sagrario and Cunney, Anna and Dunder, Kristina and Bego, Margareta and Sepodes, Bruno and Castelnovo, Thomas},
title = {The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis},
journal = {British Journal of Dermatology},
year = {2025},
volume = {193},
number = {5},
pages = {996--998},
doi = {10.1093/bjd/ljaf259}
}
EUVIMED